UNSPSC 51373407: Ammonium/antimony/cherry/codeine/pine/potassium

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373407 Ammonium/antimony/cherry/codeine/pine/potassium is a Commodity code under which state and local governments procure pharmaceuticals and related health-care products, including naloxone, over-the-counter medications, and drug deactivation systems. The code sees activity from county health departments and state cooperative purchasing alliances that aggregate demand across multiple jurisdictions. Vendors must comply with cGMP certification, Drug Supply Chain Security Act requirements, FDA approval, and federal manufacturing standards. Contracts typically include multi-year terms with quarterly or ongoing delivery schedules to designated health-care facilities, with pricing structured as fixed-fee or competitive bid arrangements.

Seminole County, Florida and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, represent the two most recent opportunities. Seminole County issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford, Florida, with a response deadline of July 26, 2023. MMCAP issued RFP S1070000015802 in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities in Minnesota and Oregon, with a response deadline of March 26, 2026. The MMCAP opportunity requires vendor participation through three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health, and Morris & Dickson Co.) and weights evaluation 75 percent on price competitiveness, 10 percent on fixed pricing, and the remainder on compliance, EDI capability, and administrative fee acceptance. Recent activity concentrates in Florida and the Upper Midwest, with the MMCAP cooperative structure suggesting broader multi-state reach across participating jurisdictions.